Bifogade filer
Kurs
-4,46%
Likviditet
0,54 MSEK
Prenumeration
Kalender
Tid* | ||
2025-02-14 | 11:30 | Bokslutskommuniké 2024 |
2024-12-10 | - | Extra Bolagsstämma 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-24 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2024-05-23 | - | Årsstämma |
2024-05-17 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-20 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2022-05-19 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-06-07 | - | Split COMBI 20:1 |
2021-05-26 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2021-05-25 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-06-30 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2020-06-29 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Kvartalsrapport 2019-Q1 |
2019-05-16 | - | Årsstämma |
2019-05-15 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2018-05-03 | - | Årsstämma |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-01-29 | - | Bokslutskommuniké 2017 |
2017-11-01 | - | Kvartalsrapport 2017-Q3 |
2017-08-17 | - | Kvartalsrapport 2017-Q2 |
2017-05-18 | - | Kvartalsrapport 2017-Q1 |
2017-05-10 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2017-05-09 | - | Årsstämma |
2017-01-31 | - | Bokslutskommuniké 2016 |
2017-01-26 | - | Extra Bolagsstämma 2017 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-17 | - | Kvartalsrapport 2016-Q2 |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-04-05 | - | X-dag ordinarie utdelning COMBI 0.00 SEK |
2016-04-04 | - | Årsstämma |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-11-19 | - | Kvartalsrapport 2015-Q3 |
2015-08-20 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Västra Hamnen Corporate Finance, in its initial analysis of the Company, values CombiGene at SEK 12.19 per share.
The analysis is the first one that Västra Hamnen has carried out of CombiGene since the collaboration began in April 2024. It is based on a risk-adjusted DCF model, which indicates a fair value. The analysis is published on Västra Hamnen's website and available here.
“Västra Hamnen's analysis highlights the potential that exists in our projects, which are aimed at large patient groups where effective and sustainable treatments are currently lacking. As our work progresses towards the set milestones, the risk in the projects decreases, which positively affects the valuation,” comments CombiGene's CEO Peter Ekolind.
Contacts
CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com
www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com
About CombiGene
CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.
Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.
Sign up here to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.